论文部分内容阅读
目的检测血清中期因子(MK)水平,探讨其在评价弥漫大B细胞淋巴瘤(DLBCL)患者病情、疗效及预后的临床意义。方法收集46例DLBCL患者治疗前后、同期20例淋巴结反应性增生患者及30例健康体检者血清标本,采用酶联免疫吸附法(ELISA)测定血清标本中的MK水平,分析其与临床特征及预后的关系。结果 DLBCL患者组化疗前血清MK水平明显高于淋巴结反应增生组及健康体检组,差异有统计学意义(P<0.05)。血清MK水平在患者性别和年龄组间差异无统计学意义(P>0.05);在不同临床分期、LDH水平、淋巴瘤类型及IPI评分组间差异有统计学意义(P<0.05),化疗有效组患者化疗前后血清MK、LDH水平明显降低,差异有统计学意义(P<0.05);无效组化疗组患者化疗前后差异无统计学意义(P>0.05),血清MK与LDH呈正相关(r=0.900,P<0.05)。结论 ELISA法测定血清MK可作为DLBCL患者的肿瘤标志物,用于评价患者的病情、化疗效果并和预后有一定的关系。
Objective To detect the level of serum midkine (MK) in patients with diffuse large B cell lymphoma (DLBCL) to evaluate its clinical significance. Methods Serum samples were collected from 46 cases of DLBCL patients before and after treatment, 20 cases of reactive hyperplasia of lymph nodes and 30 cases of healthy volunteers during the same period. The levels of MK in serum samples were detected by enzyme-linked immunosorbent assay (ELISA), and their clinical characteristics and prognosis Relationship. Results The levels of MK in patients with DLBCL before chemotherapy were significantly higher than those in lymph node reaction hyperplasia and healthy subjects (P <0.05). There was no significant difference in serum MK levels between the sexes and the age groups (P> 0.05). There was significant difference in LDH level, lymphoma type and IPI score between different clinical stages (P <0.05) and chemotherapy The levels of serum MK and LDH in patients before and after chemotherapy were significantly lower than those before chemotherapy (P <0.05). There was no significant difference between before and after chemotherapy in patients in chemotherapy group (P> 0.05) 0.900, P <0.05). Conclusion Serum MK can be used as a tumor marker in patients with DLBCL by ELISA. It can be used to evaluate the patient’s condition, chemotherapy effect and prognosis.